No­var­tis re­port­ed­ly in talks to buy Mor­phoSys; Astel­las cuts PhII pro­gram; Si­lence's $120M pri­vate place­ment

Plus, news about Ad­verum, Bridge­Bio Phar­ma, Vax­cyte, Cor­bus and Im­muno­core:

No­var­tis re­port­ed­ly in deal talks with Mor­phoSys: The Swiss Big Phar­ma is in ad­vanced talks to buy the Ger­man drug­mak­er, Reuters re­port­ed Mon­day, cit­ing un­named sources. The news out­let al­so re­port­ed that In­cyte had made an of­fer. Mor­phoSys’ mar­ket cap is cur­rent­ly about $2.2 bil­lion, and the biotech’s shares $MOR rose about 45% on the news. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER